


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0210  
Inventors: Lex M. Cowser  
Serial No.: 10/018,497  
Filing Date: December 12, 2001  
Examiner: Not Yet Assigned  
Group Art Unit: Not Yet Assigned  
Title: Antisense Modulation of G-Alpha-13  
Expression



I, **Jane Massey Licata**, Registration No. 32,257, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: March 20, 2002

Jane Massey Licata  
Jane Massey Licata, Registration No. 32,257

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

( ) The fee of \$180.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously

submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/339,775, filed June 25, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: March 20, 2002

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 02 of 02

## Form PTO-1449 Modified

List of Patents and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce

Socket No.  
RTSP-0210

Serial No.  
10/018,497

Applicant  
Lex M. Cowsert

Filing Date  
December 12, 2001

Group  
Not Yet Assigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


AI Branch A.D., "A good antisense molecule is hard to find", *TIBS* 1998 45-50

AJ Stein C.A., "Hybridization prediction gets to first base", *Nature Biotechnology* 1999 17:751-752

AK Gewirtz et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise", *Proc. Natl. Acad. Sci. USA* 1996 93:3161-3163

EXAMINER

DATE CONSIDERED



Sheet 01 of 02

Form PTO-1449 Modified		Docket No. RTSP-0210	Serial No. 10/018,497
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Lex M. Cowsert	
		Filing Date December 12, 2001	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Hamm, <i>The many faces of G protein signaling</i> , J. Biol. Chem., 1998, 273:669-672	
	AB	Kineman et al., <i>Paradoxical effects of dopamine (DA): Gi alpha 3 mediates DA inhibition of PRL release while masking its PRL-releasing activity</i> , Endocrinology, 1994, 135:790-793	
	AC	Kineman et al., <i>Role of guanine nucleotide-binding proteins, Gi alpha 3 and Gs alpha, in dopamine and thyrotropin-releasing hormone signal transduction: evidence for competition and commonality</i> , J. Endocrinol., 1996, 148:447-455	
	AD	Law et al., <i>Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2</i> , J. Biol. Chem., 1993, 268:10721-10727	
	AE	Redmond et al., <i>Flow-mediated regulation of G-protein expression in cocultured vascular smooth muscle and endothelial cells</i> , Arterioscler. Thromb. Vasc. Biol., 1998, 18:75-83	
	AF	Schmidt et al., <i>Alterations in guanine nucleotide regulatory protein expression and activity in human hepatocellular carcinoma</i> , Hepatology, 1997, 26:1189-1194	
	AG	Wise et al., <i>Interactions of the alpha2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants</i> , Biochem. J., 1997, 321:721-728	
	AH	Wu et al., <i>Inhibition of phospholipase C blocks opioid receptor-mediated activation of Gi proteins</i> , Neuroreport., 1998, 9:99-103	
EXAMINER		DATE CONSIDERED	